All In Biotech

Drug Trial Radar · NCT00433732

To Evaluate the Safety and Efficacy of Trexima in the Acute Treatment of Migraine Headaches

A Double-Blind, Multicenter, Randomized, Placebo-Controlled Single Dose Study to Evaluate the Safety and Efficacy Opf Trexima in the Acute Treatment of Migraine Headaches

Last checked: Nov 19, 2026Latest source record: Feb 12, 2007 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,400 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,400

Actual

Start

Aug 2004

Primary completion

Not stated

Study completion Apr 2005

Sponsor

Lead sponsor
POZENIndustry
Sponsor type
Industry
First posted
Feb 12, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To determine the efficacy of the Trexima versus placebo as assessed by pain relief and the incidences of photophobia, phonophobia and nausea at 2 hours after treatment as the primary endpoints.

Conditions

  • Migraine Headaches

Interventions

  • sumatriptanDrug

  • naproxen sodiumDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Trexima will be evaluated for efficacy as an acute treatment for migraine based on its superiority over placebo at 2 hours for: a) pain relief (no or mild pain), b) incidence of photophobia, c) incidence of phonophobia and d) incidence of nausea.

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Little Rock Family Practice Clinic

    Little Rock, Arkansas

  • Pozen, Inc.

    Chapel Hill, North Carolina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.